Literature DB >> 16052154

Bowen disease of the eyelid successfully treated with imiquimod.

Paul A Brannan1, Heidi K Anderson, Robert C Kersten, Dwight R Kulwin.   

Abstract

We present a case of Bowen disease affecting the eyelid that was successfully treated with imiquimod. The clinical presentation, histopathology, and treatment of this case are presented. The tumor was treated with imiquimod for 3 months, leading to complete resolution of the disease both clinically and histopathologically. There was no evidence of recurrence 5 months after treatment cessation. Imiquimod was safely used on the eyelid in this case and may avoid extensive periocular tumor excision and reconstruction in Bowen disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16052154     DOI: 10.1097/01.iop.0000170421.07098.61

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  5 in total

1.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

Review 2.  Treatment of periocular lentigo maligna with topical 5% Imiquimod: a review.

Authors:  Inga Neumann; R Patalay; M Kaushik; H Timlin; C Daniel
Journal:  Eye (Lond)       Date:  2022-07-14       Impact factor: 4.456

3.  Giant extragenital Bowen's disease.

Authors:  Ilko Bakardzhiev; Anastasiya Atanasova Chokoeva; Georgi Tchernev
Journal:  Wien Med Wochenschr       Date:  2015-11-05

4.  Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area.

Authors:  Gamze Ozturk Karabulut; Pelin Kaynak; Can Ozturker; Korhan Fazil; Osman Bulut Ocak; Muhittin Taskapılı
Journal:  Indian J Ophthalmol       Date:  2017-01       Impact factor: 1.848

5.  Bowen's disease - a review of newer treatment options.

Authors:  Thorsten Neubert; Percy Lehmann
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.